LAS VEGAS & BOSTON - nvtip -- LAS VEGAS, NV – CovInnovations, a clinical-stage targeted COVID-19 therapeutic, diagnostic, and assessment company, today announced the appointment of Jamie Jones as Chief Executive Officer (CEO). Mr. Jones will also join the Company's Board of Directors. Aury Nagy, MD, FAANS, will continue to lead the research and development (R&D) organization as Chief Science Officer and Board Chairman.

"I've led and founded CovInnovations since 2020 and am proud of developing our innovative portfolio of breakthrough therapies and diagnostics, including COVI-001, our novel immune modulator, for which we are on track to start our pivotal phase II/III trials in the US in the fourth quarter of 2022," said Dr. Nagy. "Jamie brings broad global business development, product launch experience, and a proven track record in leading successful, high-performing life science companies. I am confident in Jamie's abilities to lead CovInnovations through its next chapter as we bring COVI-001 and more novel COVID-19 technologies to patients."

More on nvtip.com

• Powering the Next Frontier of the $1 Trillion Space Economy: Ascent Solar Technologies (N A S D A Q: ASTI)
• Taikan's T-V856S VMC Earns Prestigious 2025 Vogel Global Pioneer Award
• Flick Truck Accident Law Joins the Commercial Vehicle Safety Alliance to Strengthen Truck Safety Advocacy
• PebblePad Announces Global Partnership with Inside Higher Ed and Times Higher Education
• Passion Struck Network Debuts: A Creator-First Platform for Purpose-Driven Podcasting and Human Impact

"I am humbled and happy to lead CovInnovations and partner alongside the amazingly skilled people of this flourishing company to continue our trajectory," said Mr. Jones. "Dr. Nagy and former interim CEO Kristine Leavitt have successfully led CovInnovations with an unequaled purpose for patients, science, and people."

Mr. Jones added, "CovInnovations has an unprecedented opportunity as we transition from developing to commercializing therapeutics that transform the way COVID-19 is treated and meaningfully impact the lives of millions of patients. Our innovative COVID-19 portfolio includes one late-stage clinical asset, COVI-001, and a promising pipeline, which includes a rapid-RNA test for home use with encrypted outcome identifiers and a test to determine the likelihood of contracting symptomatic COVID."

Jamie Jones has thirty years of industry experience. He held executive leadership positions in early-stage and late-stage biotechnology companies. Mr. Jones most recently served as Chief Business Officer of DoubleRainbow Biosciences. He led the company's transformation from a research startup to a dual platform drug development company during his tenure. Jamie holds a Bachelor of Science in Finance and MBA from the University of Central Florida in Orlando, Florida.

More on nvtip.com

• The Aligned Woman Is It Well With Your Soul
• Jonathan Malveaux Named Newest Member of Forbes Business Council
• NFL Midseason 2025: Who's for Real and Who's Faking It?
• Silver Ball, Golden Heart: Dallas-Area Pinball Wizards Flip for Charity at Side Quest Arcade
• Sweet Beginnings: Sugar Queen Dessert Shop Opens in the Colony Ridge Community

CovInnovations creates technologies and solutions directly related to the COVID-19 pandemic. The company's patent-pending treatments and technologies seek to create a new standard of care in the battle against this disease. CovInnovations products feature groundbreaking technologies that assess, diagnose and treat COVID-19 to help integrate our world into pre-pandemic times. Dr. Aury Nagy, M.D. FAANS, a neurosurgeon practicing in Las Vegas, is the founder of CovInnovations.

Contact: info@covinnovations.com

CovInnovations^TM
3012 South Durango Drive Las Vegas, NV 89117
Office: 833-702-1888
www.covinnovations.com